2 colajacky unn en bier von 4 bis jetzt. lol
Anzeige
Meldung des Tages: Der nächste Gold-Hebel? 200 Meter Treffer, volle Kassen – warum diese Aktie jetzt auffällt
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter
... 55 56 57 59 60 61 ...
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter ... 55 56 57 59 60 61 ...
Genta - der letzte Thread
Beiträge:
13.263
Zugriffe: 2.228.945 / Heute: 179
Zugriffe: 2.228.945 / Heute: 179
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
16:17:33 0,568 675
16:16:48 0,577 500
16:16:42 0,577 1800
16:16:30 0,560 2000
16:16:24 0,575 1000
16:15:11 0,570 700
16:14:13 0,570 1000
16:13:48 0,535 1000
16:13:13 0,570 1000
16:13:09 0,557 5601
16:16:48 0,577 500
16:16:42 0,577 1800
16:16:30 0,560 2000
16:16:24 0,575 1000
16:15:11 0,570 700
16:14:13 0,570 1000
16:13:48 0,535 1000
16:13:13 0,570 1000
16:13:09 0,557 5601
is ja dick im Minus, scheint nicht so gut der start bei den Burgerboys
dass die Amis den Kurs runterprügeln zum Auftakt... machen die sooo oft... hätte ich mal alle verkauft und wieder eingesammelt. Aber nachher weiss man es immer besser.
das problem hab ich grade auch! Ich hab so eine voranhnung gehabt mit dem kauf noch zu warten, aber jetzt is zu spät
vielleicht bei höheren kursen ;)
die sucht hat mich hier wieder voll im griff
bei infineon passiert, verkauft um wieder zu kaufen ( war so wie heute) bis ich sie bekommen habe
waren sie dann teurer.
waren sie dann teurer.
runtergeprügelt? Die haben den Kurs gestern (zum Schluss) noch hochgeprügelt...
über den Dollar? war wohl ne Schüttel-Aktion um billig an euere Shares zu kommen :-))
100%
bei so einem anstieg gabs fast immer solche rücksetzer
also jetzt gehts richtung 1,20 usd?!!!!!
bei so einem anstieg gabs fast immer solche rücksetzer
also jetzt gehts richtung 1,20 usd?!!!!!
2009-09-18 09:20 ET - News Release
CALGARY, Alberta, Sept. 18, 2009 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Genta Incorporated (OTCBB:GETA). Skymark Research is currently offering a complimentary trial subscription. To view our research go to: www.skymarkresearch.com
About SMR:
Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentary and the SMR newsletter. Skymark Research's staff of small-cap investment professionals is dedicated to providing the small market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to www.skymarkresearch.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.skymarkresearch.com/signup.php
About Genta Incorporated (OTCBB:GETA):
Genta Incorporated (OTCBB:GETA) is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, which has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States.
SMR Disclosure:
Skymarkresearch.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Skymark Research has not been compensated by any of the above mentioned companies. Please read our report and visit our Web site, www.skymarkresearch.com, for complete risks and disclosures.
CALGARY, Alberta, Sept. 18, 2009 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Genta Incorporated (OTCBB:GETA). Skymark Research is currently offering a complimentary trial subscription. To view our research go to: www.skymarkresearch.com
About SMR:
Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentary and the SMR newsletter. Skymark Research's staff of small-cap investment professionals is dedicated to providing the small market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to www.skymarkresearch.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.skymarkresearch.com/signup.php
About Genta Incorporated (OTCBB:GETA):
Genta Incorporated (OTCBB:GETA) is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, which has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States.
SMR Disclosure:
Skymarkresearch.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Skymark Research has not been compensated by any of the above mentioned companies. Please read our report and visit our Web site, www.skymarkresearch.com, for complete risks and disclosures.
Gruß S.
Time Ex Price Change Volume
10:38:46 Q 0.87 -0.065 200
10:38:45 Q 0.86 -0.075 300
10:38:45 Q 0.87 -0.065 5,000
10:38:33 Q 0.851 -0.084 3,000
10:38:33 Q 0.851 -0.084 5,000
10:38:33 Q 0.851 -0.084 1,933
10:38:33 Q 0.851 -0.084 100
10:38:33 Q 0.851 -0.084 600
10:38:24 Q 0.85 -0.085 5,000
10:38:22 Q 0.85 -0.085 5,000
10:38:46 Q 0.87 -0.065 200
10:38:45 Q 0.86 -0.075 300
10:38:45 Q 0.87 -0.065 5,000
10:38:33 Q 0.851 -0.084 3,000
10:38:33 Q 0.851 -0.084 5,000
10:38:33 Q 0.851 -0.084 1,933
10:38:33 Q 0.851 -0.084 100
10:38:33 Q 0.851 -0.084 600
10:38:24 Q 0.85 -0.085 5,000
10:38:22 Q 0.85 -0.085 5,000
Gruß S.
wie gesagt da hat der Makler noch jemanden schnell reingelassen, alte leier hast viel geld kommste überall rein
IMHO. God bless our investments
ich liebe dich :)
wenn du eine Frau wärst hätte ich dich glatt geheiratet :)
wenn du eine Frau wärst hätte ich dich glatt geheiratet :)
hat was. Gut, dass wir das Spiel durchschauen. Einzigste Gegenwaffen sind Geduld und Zeit.
Stay long and strong.
Meine Wamus ziehen auch wieder an.
Stay long and strong.
Meine Wamus ziehen auch wieder an.
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Genta Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 302 | Gensense ist Tod es lebe Tesetaxel! | raurunter | raurunter | 25.04.21 13:15 | |
| 10 | 2.653 | Die 1000% Chance noch dieses Jahr.... | Happydepot | steven-bln | 25.04.21 13:13 | |
| 13 | 2.456 | Analyse. GENTA Kursexplosionsgefahr!! | brunneta | steven-bln | 25.04.21 02:54 | |
| 4 | 1.447 | was mit der Aktie passiert, etc.. | Lucky2020 | Lucky2020 | 25.04.21 02:10 | |
| 622 | Hoffnung stirbt zum Schluss...! | raurunter | raurunter | 25.04.21 00:48 |